or Try an Advanced Search...

    Portola Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    RIGL B Rigel Pharmaceuticals, Inc. 5.15
    BIIB F Biogen Idec Inc. -1.59
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major
    Related Stock Lists: Lupus Adenosine Alzheimer's Disease Asthma Autoimmune Disease Autoimmune Disorders Biotechnology Cancer Cancer Cell Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Clinical Trial Product Clinical Trial Products Daiichi Sankyo Degenerative Disease Disability Discoid Lupus Drug Development Enzymes

    Related ETFs - A few ETFs which own one or more of the above listed Portola Pharmaceuticals stocks.

    Symbol Grade Name Weight
    BIS B ProShares UltraShort Nasdaq Biotechnology 6.12
    PBE C PowerShares Dynamic Biotech & Genome 4.21
    BBH D Market Vectors Biotech ETF 3.86
    MNTL F Tema Neuroscience and Mental Health ETF 3.57
    MEDX F Horizon Kinetics Medical ETF 3.08
    View all Portola Pharmaceuticals ETFs...
    Compare ETFs
    Compare BBH to MEDX Compare BBH to MNTL Compare BIS to MNTL

        Portola Pharmaceuticals Stocks Recent News

        Date Stock Title
        Nov 20 BIIB Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
        Nov 19 BIIB Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
        Nov 19 RIGL How Much Upside is Left in Rigel (RIGL)? Wall Street Analysts Think 28.28%
        Nov 19 RIGL Zacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street Interactive
        Nov 19 BIIB Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
        Nov 18 RIGL 5 Relative Price Strength Options Available for Investors
        Nov 18 BIIB Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
        Nov 18 BIIB Needham downgrades Biogen on slow growth of Alzheimer's drug
        Nov 18 BIIB Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
        Nov 18 BIIB Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
        Nov 18 BIIB Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
        Nov 15 RIGL Exploring Three High Growth Tech Stocks in the United States
        Nov 15 BIIB Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
        Nov 14 BIIB European committee takes a second look at Alzheimer's drug and now says it should be approved
        Nov 14 BIIB 5 Healthcare Stocks to Buy in a Beaten-Up Sector
        Nov 14 BIIB Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
        Nov 14 BIIB Biogen gains as Eisai wins EU nod for Alzheimer’s drug
        Nov 14 BIIB Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
        Nov 14 BIIB Peeling Back The Layers: Exploring Biogen Through Analyst Insights
        Nov 14 BIIB Citi initiates coverage on 5 new biotech stocks
        Related Industries: Biotechnology Drug Manufacturers - Major
        Related Stock Lists: Lupus Adenosine Alzheimer's Disease Asthma Autoimmune Disease Autoimmune Disorders Biotechnology Cancer Cancer Cell Cd20 Chemical Compounds Chronic Lymphocytic Leukemia Clinical Trial Product Clinical Trial Products Daiichi Sankyo Degenerative Disease Disability Discoid Lupus Drug Development Enzymes
        Portola Pharmaceuticals

        Portola Pharmaceuticals is an American clinical stage biotechnology company that researches, develops and commercializes drugs. The company focuses primarily on drugs used in the treatment of thrombosis and hematological malignancies.
        Headquartered and founded in South San Francisco, California, Portola Pharmaceuticals is a member of the NASDAQ Biotechnology Index.

        More about Portola Pharmaceuticals
        Browse All Tags